6. Treatment Options and Individualized Care

To understand the treatment options available and be able to discuss them appropriately to provide individualised patient care

Full content only available after log-in

6.1.  Knows the different treatment modalities for IBD taking into account disease extent, activity, previous history and complications

6.2.  Knows the modes of delivery of different drug therapies and their advantages and disadvantages

6.3.  Recognises the importance of patient choice in deciding therapy and in helping to ensure adherence

6.4.  Understands the evidence base behind different therapeutic strategies and when they might be appropriate (conventional step care, optimised step up, top down and treat to target)

6.5.  Appreciates the monitoring requirements for specific therapies

6.6.  Appreciates common side effects and complications of therapy, their frequency and how to manage them

6.7.  Appreciates the importance of on-going disease monitoring to confirm efficacy

6.8.  Understands when surgery is the most appropriate therapeutic option

6.9.  Is up to date with the evidence base from current clinical trial and real world data sets for the use of available therapies

6.10.  Has knowledge of the role of optimising therapy including interpretation of therapeutic drug monitoring for conventional and biological therapies

6.11.  Appreciates the role of stopping medical therapies in IBD and the appropriate timing / patient population in whom drugs can be stopped


Programme Phase:

Content Format:

Topic 6.3 : Educational update


P BAger

ECCO 2017 Barcelona Congress

Webcast + PPT

Topic 6.5 : Educational update

Monitoring drug therapy with biomarkers, drug levels and antibody testing

P Irving

13th IBD Intensive Advanced Course Session


Topic 6.8 : Educational update

Managing IBD and pregnancy

J van der Woude, I Dotan

15th IBD Intensive Advanced Course

Webcast + PPT

Topic 6.9 : State of the art

The science behind biosimilars

C Gonzalo

ECCO 2015 Barcelona Congress


Topic 6.9 : State of the art

Experience with biosimilars from rheumatology

U Mueller-Ladner

ECCO 2015 Barcelona Congress


Topic 6.9 : State of the art

Unanswered questions on biosimilars in IBD

S Schreiber

ECCO 2015 Barcelona Congress


Topic 6.10 : State of the art

Understanding pharmacokinetics and immunogenicity of anti-TNFs

A Gills

ECCO 2015 Barcelona Congress


Topic 6.10 : State of the art

Applying pharmacockinetics in the daily care of patients: From combination therapy to therapeutic drug monitoring

B Levesque

ECCO 2015 Barcelona Congress


Topic 6.11 : State of the art

Stopping drugs

C Lees

ECCO 2016 Amsterdam Congress


Topic 6.6 : Educational update

Adverse events of corticosteroid therapy

Antonio López-Sanromán